Protobios is a life sciences company that utilizes next generation immunoprofiling technology (MVA™) to drive research in cancer and other immune-mediated diseases.
Since founding, we have contributed to the development of high-tech tools for clinical use. In the recent years, in the field of immunology. We will continue to maintain our focus, today and tomorrow, on novel solutions and will always be interested in combined joint expertise that will help lead us to the next series of inventions.
Mission and Vision
Our company, together with clinical, translational science and IT leaders across the world, is developing ways to facilitate innovation for improving the future healthcare – we make diagnostics easy and precision medicine affordable.
We set out to offer our clients in clinical diagnostics and therapeutic development accurate, safe and cost-effective solutions by using a high-throughput cutting-edge screening platform not constrained by the problems facing conventional research tools. By doing this, we are able to offer customized solutions. No loss in the quality.
A strong company needs driven and hard-working team. The innovative minds behind Protobios are:
Industrial PhD programme
What We Do
Strong Academic background
In 2017, Protobios’ R&D was assessed by external panel of experts of Estonian Research Council, and the company was granted for the next 7 years a positive evaluation as a R&D institution in the field of biomedical sciences (http://www.etag.ee/en/activities/rd-evaluation/).
Immunoprofiling by employing MVA™
mRNA alternative splicing to identify cell-specific changes in core transcription.
Functional studies of stem cells.
International academic and industrial partnerships
– Organizer of clinical research events
– Participant and coordinator of research fellowship programs
– epitope mapping, immunoprofiling analysis, biomarker development
– qualitative and quantitative measurements of drugs, metabolites and biomarkers (DNA, RNA, proteins, cells) across a variety of matrices